Track record
Every buy, sell, and watch call Biotech Distilled has published — scored against XBI, the biotech index.
As of Nov 17, 2026 · hypothetical editorial record, not investment advice
How to read this page
- Buy
- A buy call I published — Core = higher conviction.
- Spec buy
- A speculative buy — higher risk, smaller-size idea.
- Avoid
- A call to stay away — scored by the loss it sidestepped.
- Buy▵
- Conviction changed since the call opened — e.g. opened as a Spec buy, now a Buy. The badge shows today's conviction; the linked post is the opening call. Hover the badge for the date it changed.
- Entry
- The first closing price after I published the call — if I posted after the 4pm ET close, that's the next session's close, since it's the first price you could actually have traded at.
- Now
- The latest available closing price — on a closed call, the price it exited at, not today's price.
- Return
- Percent change from Entry to Now. Read it with the call type: on a buy, higher is better; on an avoid it is the stock's move, so a big positive number means the avoid was wrong. vs XBI is the column that scores every call the same way.
- vs XBI
- XBI is the biotech index ETF. This is Return minus XBI's return over the same dates — the value added beyond just buying the index. For avoids, the loss saved vs holding XBI.
- Dates
- Opened and Closed are the market sessions the call was priced at, which is usually the session after the post — a call published after the 4pm ET bell on a Friday prices on Monday. Hover a date to see which post it came from.
- Open / Closed
- Open = still live. Closed = realized; the return runs to the first close after I flipped the call. Where a buyout settled at a known cash price, I use that instead.
Top buy calls
| Call | Buy | Now | Return | vs XBI |
|---|---|---|---|---|
| ETON Eton Pharmaceuticals Buy | $18.22 | $63.65 | +249.3% | +234.7 |
| SYRE Spyre Therapeutics Buy | $33.47 | $93.81 | +180.3% | +158.8 |
| XERS Xeris Biopharma Spec buy | $7.93 | $16.80 | +111.9% | +119.5 |
| REPL Replimune Group Buy | $9.00 | $19.69 | +118.8% | +109.9 |
| CAPR Capricor Therapeutics Spec buy | $4.17 | $8.41 | +101.7% | +106 |
| DRTS Alpha Tau Medical Spec buy | $5.90 | $12.09 | +104.9% | +90 |
| DFTX Definium Therapeutics Buy | $15.02 | $29.38 | +95.6% | +81 |
| LQDA Liquidia Spec buy | $33.94 | $56.73 | +67.1% | +68.2 |
| XNCR Xencor Buy | $21.49 | $34.50 | +60.5% | +64.6 |
| EXEL Exelixis Spec buy | $41.36 | $68.50 | +65.6% | +49.2 |
What I told you to avoid
| Call | Since | Stock | Saved vs XBI |
|---|---|---|---|
| RVPH Reviva Pharmaceuticals Avoid | Jan 26, 2026 | -94.1% | +107.9 |
| APVO Aptevo Therapeutics Avoid | Jun 16, 2026 | -89.8% | +97.2 |
| NRSN NeuroSense Therapeutics Avoid | Jul 13, 2026 | -89.7% | +83.2 |
| LGVN Longeveron Avoid | May 11, 2026 | -74.8% | +82.6 |
| ACTU Actuate Therapeutics Avoid | Jul 20, 2026 | -82% | +78.3 |
| IXHL Incannex Healthcare Avoid | Mar 16, 2026 | -47.4% | +64.7 |
| OTLK Outlook Therapeutics Avoid | Jul 27, 2026 | -66.1% | +62.6 |
| MRKR Marker Therapeutics Avoid | Mar 16, 2026 | -40.4% | +57.7 |
Calls that paid off
Buy calls I closed in the green — including takeouts. Entry → exit, realized.
| Call | Bought | Exited | Return | vs XBI |
|---|---|---|---|---|
| FBRX Forte Biosciences Acquired | Apr 6, 2026 | Jul 28, 2026 | +189.9% | +173.6 |
| CRNX Crinetics Pharmaceuticals Acquired | Apr 2, 2026 | Jul 7, 2026 | +124.4% | +97.3 |
| ATAI Atai Beckley Acquired | Dec 24, 2025 | Jul 17, 2026 | +72.3% | +50.2 |
| APGE Apogee Therapeutics Acquired | May 5, 2026 | Jun 23, 2026 | +59.5% | +49.6 |
| CNTA Centessa Pharmaceuticals plc Acquired | Mar 16, 2026 | Jun 23, 2026 | +43.2% | +24.4 |
| QURE uniQure Spec buy | Jun 18, 2026 | Jun 23, 2026 | +5.9% | +1.4 |
| ENTA Enanta Pharmaceuticals Buy | Feb 17, 2026 | Jul 6, 2026 | +4.7% | -24.5 |
Every call
| Call | Entry | Now | Return | vs XBI | Status | Opened |
|---|---|---|---|---|---|---|
| ETON Eton Pharmaceuticals Buy | $18.22 | $63.65 | +249.3% | +234.7 | Open | Feb 19, 2026 |
| FBRX Forte Biosciences Buy▵ | $26.44 | $76.65 | +189.9% | +173.6 | Closed Jul 28, 2026 | Apr 6, 2026 |
| SYRE Spyre Therapeutics Buy | $33.47 | $93.81 | +180.3% | +158.8 | Open | Dec 18, 2025 |
| XERS Xeris Biopharma Spec buy | $7.93 | $16.80 | +111.9% | +119.5 | Open | Aug 7, 2026 |
| REPL Replimune Group Buy▵ | $9.00 | $19.69 | +118.8% | +109.9 | Open | Jun 1, 2026 |
| RVPH Reviva Pharmaceuticals Avoid | $6.04 | $0.35 | -94.1% | +107.9 | Open | Jan 26, 2026 |
| CAPR Capricor Therapeutics Spec buy | $4.17 | $8.41 | +101.7% | +106 | Open | Aug 4, 2026 |
| CRNX Crinetics Pharmaceuticals Buy | $37.23 | $83.53 | +124.4% | +97.3 | Closed Jul 7, 2026 | Apr 2, 2026 |
| APVO Aptevo Therapeutics Avoid | $4.54 | $0.46 | -89.8% | +97.2 | Open | Jun 16, 2026 |
| DRTS Alpha Tau Medical Spec buy | $5.90 | $12.09 | +104.9% | +90 | Open | Jan 7, 2026 |
| GOSS Gossamer Bio Avoid | $34.29 | $14.00 | -59.2% | +88.9 | Closed Aug 24, 2026 | Mar 2, 2026 |
| NRSN NeuroSense Therapeutics Avoid | $14.60 | $1.51 | -89.7% | +83.2 | Open | Jul 13, 2026 |
| LGVN Longeveron Avoid | $8.38 | $2.11 | -74.8% | +82.6 | Open | May 11, 2026 |
| DFTX Definium Therapeutics Buy | $15.02 | $29.38 | +95.6% | +81 | Open | Jan 14, 2026 |
| ACTU Actuate Therapeutics Avoid | $1.40 | $0.25 | -82% | +78.3 | Open | Jul 20, 2026 |
| LQDA Liquidia Spec buy | $33.94 | $56.73 | +67.1% | +68.2 | Open | Oct 14, 2026 |
| IXHL Incannex Healthcare Avoid | $3.31 | $1.74 | -47.4% | +64.7 | Open | Mar 16, 2026 |
| XNCR Xencor Buy▵ | $21.49 | $34.50 | +60.5% | +64.6 | Open | Jul 30, 2026 |
| OTLK Outlook Therapeutics Avoid | $1.06 | $0.36 | -66.1% | +62.6 | Open | Jul 27, 2026 |
| ACTU Actuate Therapeutics Avoid | $6.49 | $2.89 | -55.5% | +62.2 | Closed May 12, 2026 | Jan 7, 2026 |
| VNDA Vanda Pharmaceuticals Avoid | $6.20 | $4.00 | -35.5% | +61.9 | Closed Oct 28, 2026 | Feb 17, 2026 |
| MRKR Marker Therapeutics Avoid | $1.41 | $0.84 | -40.4% | +57.7 | Open | Mar 16, 2026 |
| KAPA Kairos Pharma Avoid | $2.17 | $0.87 | -59.9% | +53.7 | Closed Oct 7, 2026 | Aug 18, 2026 |
| PHIO Phio Pharmaceuticals Avoid | $1.32 | $0.72 | -45.7% | +52.2 | Open | Apr 15, 2026 |
| ATAI Atai Beckley Spec buy | $4.19 | $7.22 | +72.3% | +50.2 | Closed Jul 17, 2026 | Dec 24, 2025 |
| APGE Apogee Therapeutics Buy | $83.29 | $132.88 | +59.5% | +49.6 | Closed Jun 23, 2026 | May 5, 2026 |
| EXEL Exelixis Spec buy▵ | $41.36 | $68.50 | +65.6% | +49.2 | Open | Jan 30, 2026 |
| ELTX Elicio Therapeutics Avoid | $3.29 | $1.43 | -56.6% | +46.9 | Open | Jul 6, 2026 |
| EVMN Evommune Avoid | $13.29 | $6.92 | -47.9% | +45.5 | Closed Oct 2, 2026 | Jun 30, 2026 |
| ORKA Oruka Therapeutics Buy | $63.18 | $96.32 | +52.5% | +45.5 | Open | May 13, 2026 |
| CING Cingulate Avoid | $5.84 | $5.09 | -12.8% | +45.4 | Closed Aug 14, 2026 | Mar 30, 2026 |
| PYPD PolyPid Spec buy | $4.78 | $6.54 | +36.8% | +44.2 | Open | Aug 13, 2026 |
| PEPG PepGen Buy▵ | $2.85 | $3.88 | +36.1% | +43.8 | Open | Aug 7, 2026 |
| PCSA Processa Pharmaceuticals Avoid | $2.87 | $2.04 | -28.9% | +43.6 | Closed Jul 30, 2026 | Apr 13, 2026 |
| ONCY Oncolytics Biotech Avoid | $0.77 | $0.38 | -50.6% | +42.5 | Open | Sep 17, 2026 |
| CMPX Compass Therapeutics Avoid | $1.17 | $0.61 | -48.1% | +41.7 | Open | Sep 23, 2026 |
| IBRX ImmunityBio Buy▵ | $3.95 | $6.26 | +58.5% | +41.5 | Open | Jan 15, 2026 |
| CRBU Caribou Biosciences Avoid | $0.62 | $0.34 | -44.7% | +41.4 | Open | Oct 7, 2026 |
| BMEA Biomea Fusion Avoid | $0.84 | $0.49 | -41.6% | +38.6 | Open | Oct 15, 2026 |
| TLSA Tiziana Life Sciences Avoid | $1.11 | $0.65 | -41.4% | +37.7 | Open | Oct 6, 2026 |
| IVVD Invivyd Avoid | $0.96 | $0.51 | -46.8% | +36.5 | Open | Sep 22, 2026 |
| ALDX Aldeyra Therapeutics Avoid | $1.23 | $0.69 | -43.6% | +35.7 | Open | Sep 30, 2026 |
| PTN Palatin Technologies Avoid | $9.12 | $5.36 | -41.2% | +33.9 | Open | Sep 29, 2026 |
| CGON CG Oncology Buy | $53.81 | $78.94 | +46.7% | +33.2 | Open | Jan 23, 2026 |
| MBRX Moleculin Biotech Avoid | $11.34 | $6.83 | -39.8% | +32.9 | Open | Sep 24, 2026 |
| SION Sionna Therapeutics Avoid | $5.10 | $3.07 | -39.8% | +31.7 | Open | Aug 11, 2026 |
| FATE Fate Therapeutics Avoid | $1.61 | $1.02 | -36.6% | +29.6 | Open | Nov 11, 2026 |
| KYMR Kymera Therapeutics Buy | $87.35 | $121.52 | +39.1% | +28.9 | Open | Apr 9, 2026 |
| COYA Coya Therapeutics Avoid | $4.34 | $3.02 | -30.4% | +27.4 | Open | Oct 15, 2026 |
| GANX Gain Therapeutics Avoid | $1.71 | $1.18 | -31% | +25.1 | Open | Oct 2, 2026 |
| CNTA Centessa Pharmaceuticals plc Buy | $28.29 | $40.50 | +43.2% | +24.4 | Closed Jun 23, 2026 | Mar 16, 2026 |
| EYPT EyePoint Avoid | $0.41 | $0.30 | -26.8% | +21.6 | Open | Oct 20, 2026 |
| HURA TuHURA Biosciences Avoid | $1.81 | $1.40 | -22.7% | +21.6 | Open | Oct 13, 2026 |
| TVTX Travere Therapeutics Buy | $40.29 | $51.10 | +26.8% | +21.4 | Open | Apr 20, 2026 |
| KPRX Kiora Pharmaceuticals Avoid | $1.23 | $0.93 | -24.4% | +20.9 | Open | Nov 13, 2026 |
| ABSI Absci Buy▵ | $5.90 | $7.58 | +28.5% | +20.6 | Open | May 8, 2026 |
| ZURA Zura Bio Avoid | $1.41 | $1.03 | -26.3% | +20 | Open | Nov 10, 2026 |
| TTRX Turn Therapeutics Spec buy | $6.42 | $8.55 | +33.2% | +19.5 | Open | Jun 2, 2026 |
| CHRS Coherus Oncology Avoid | $0.64 | $0.48 | -25.3% | +19 | Open | Nov 10, 2026 |
| MDNAF Medicenna Therapeutics Avoid | $0.40 | $0.32 | -20% | +17.6 | Closed May 20, 2026 | May 14, 2026 |
| VSTM Verastem Buy▵ | $6.74 | $7.41 | +9.9% | +17.6 | Open | Aug 7, 2026 |
| ZYME Zymeworks Buy▵ | $23.54 | $25.84 | +9.8% | +17.5 | Open | Aug 7, 2026 |
| HELP Helus Pharma Spec buy | $6.61 | $7.20 | +8.9% | +17.1 | Open | Jun 30, 2026 |
| CLRB Cellectar Biosciences Avoid | $1.21 | $0.92 | -24% | +16.9 | Open | Nov 11, 2026 |
| HELP Helus Pharma Avoid | $5.52 | $4.32 | -21.7% | +15.2 | Closed Mar 30, 2026 | Mar 9, 2026 |
| IRD Opus Genetics Spec buy | $3.71 | $4.05 | +9.2% | +13.5 | Open | Aug 4, 2026 |
| IMVT Immunovant Buy | $26.08 | $33.21 | +27.3% | +13.3 | Open | Feb 2, 2026 |
| UNCY Unicycive Therapeutics Avoid | $5.13 | $4.70 | -8.5% | +13.3 | Closed Sep 30, 2026 | Jul 27, 2026 |
| VOR Vor Biopharma Spec buy | $14.63 | $18.18 | +24.3% | +13.1 | Open | May 15, 2026 |
| ARDX Ardelyx Avoid | $4.00 | $3.18 | -20.5% | +12.8 | Open | Aug 7, 2026 |
| CYDY CytoDyn Avoid | $0.37 | $0.32 | -13.5% | +11.1 | Closed Apr 27, 2026 | Apr 21, 2026 |
| OVID Ovid Therapeutics Spec buy | $1.81 | $2.22 | +22.7% | +9.6 | Open | Jan 27, 2026 |
| CADL Candel Therapeutics Avoid | $6.20 | $5.40 | -12.9% | +9.4 | Open | Nov 13, 2026 |
| MESO Mesoblast Avoid | $13.27 | $11.91 | -10.2% | +6.7 | Open | Nov 13, 2026 |
| BCTX BriaCell Therapeutics Avoid | $3.31 | $3.51 | +6% | +5.9 | Open | Jun 3, 2026 |
| PMVP PMV Pharmaceuticals Spec buy | $1.29 | $1.22 | -5.4% | +5.7 | Open | Sep 1, 2026 |
| OCGN Ocugen Avoid | $0.78 | $0.76 | -2.9% | +3.6 | Open | Oct 16, 2026 |
| FHTX Foghorn Therapeutics Avoid | $2.02 | $1.83 | -9.4% | +3.5 | Open | Oct 2, 2026 |
| OLMA Olema Pharmaceuticals Avoid | $8.04 | $7.22 | -10.2% | +3.1 | Open | Nov 11, 2026 |
| CRVO CervoMed Avoid | $2.44 | $2.86 | +17.2% | +2 | Closed Aug 10, 2026 | Jun 11, 2026 |
| ARTV Artiva Biotherapeutics Avoid | $4.28 | $3.86 | -9.7% | +1.9 | Open | Oct 28, 2026 |
| IMUX Immunic Spec buy | $7.23 | $7.33 | +1.4% | +1.8 | Open | Nov 16, 2026 |
| SGMT Sagimet Biosciences Spec buy | $8.75 | $9.85 | +12.6% | +1.8 | Open | Apr 28, 2026 |
| ZBIO Zenas BioPharma Spec buy | $29.51 | $27.75 | -6% | +1.7 | Open | Aug 14, 2026 |
| IRON Disc Medicine Buy | $79.48 | $76.57 | -3.7% | +1.5 | Open | Oct 20, 2026 |
| GRCE Grace Therapeutics Avoid | $2.16 | $2.10 | -2.8% | +1.4 | Closed Apr 28, 2026 | Apr 27, 2026 |
| QURE uniQure Spec buy | $46.29 | $49.04 | +5.9% | +1.4 | Closed Jun 23, 2026 | Jun 18, 2026 |
| KAPA Kairos Pharma Avoid | $0.41 | $0.40 | -1.7% | +1.3 | Open | Nov 16, 2026 |
| SPRB Spruce Biosciences Buy▵ | $41.60 | $40.49 | -2.7% | +0.3 | Open | Jul 28, 2026 |
| GHRS GH Research Buy▵ | $15.75 | $18.27 | +16% | 0 | Open | Jan 20, 2026 |
| CNTB Connect Biopharma Avoid | $0.58 | $0.58 | 0% | 0 | Open | Nov 17, 2026 |
| ABOS Acumen Pharmaceuticals Avoid | $0.24 | $0.23 | -4.2% | -0.3 | Open | Nov 2, 2026 |
| AARD Aardvark Therapeutics Avoid | $1.20 | $1.15 | -4.2% | -0.3 | Open | Nov 2, 2026 |
| NKTX Nkarta Spec buy | $1.35 | $1.25 | -7.4% | -1.1 | Open | Nov 10, 2026 |
| CLYM Climb Bio Buy▵ | $8.78 | $9.78 | +11.4% | -1.3 | Open | Apr 29, 2026 |
| IMNM Immunome Spec buy | $17.91 | $17.18 | -4% | -1.9 | Open | Nov 5, 2026 |
| IONS Ionis Pharmaceuticals Avoid | $28.19 | $26.96 | -4.4% | -1.9 | Open | Nov 10, 2026 |
| RYTM Rhythm Pharmaceuticals Buy | $102.59 | $116.61 | +13.7% | -2.3 | Open | Jan 20, 2026 |
| BLTE Belite Bio Spec buy | $178.94 | $157.72 | -11.9% | -3 | Open | Aug 12, 2026 |
| HROW Harrow Avoid | $30.36 | $29.52 | -2.8% | -3.5 | Open | Nov 10, 2026 |
| AXSM Axsome Therapeutics Avoid | $139.61 | $135.95 | -2.6% | -3.6 | Open | Nov 3, 2026 |
| AKBA Akebia Therapeutics Avoid | $0.40 | $0.40 | -0.2% | -4.3 | Closed Nov 17, 2026 | Nov 6, 2026 |
| CRDL Cardiol Therapeutics Avoid | $1.01 | $0.97 | -3.8% | -4.9 | Open | Nov 4, 2026 |
| PTGX Protagonist Therapeutics Buy | $147.75 | $124.67 | -15.6% | -5 | Open | Aug 31, 2026 |
| IMCR Immunocore Spec buy | $32.00 | $27.81 | -13.1% | -5.8 | Open | Sep 18, 2026 |
| GERN Geron Avoid | $0.95 | $0.95 | 0% | -6 | Closed Nov 5, 2026 | Oct 29, 2026 |
| RVMD Revolution Medicines Buy | $177.65 | $162.69 | -8.4% | -6.3 | Open | Nov 5, 2026 |
| FBIO Fortress Biotech Avoid | $1.71 | $1.82 | +6.4% | -6.8 | Open | Nov 16, 2026 |
| PCVX Vaxcyte Buy | $66.70 | $59.40 | -10.9% | -7.2 | Open | Oct 6, 2026 |
| CMMB Chemomab Therapeutics Avoid | $1.64 | $1.64 | 0% | -7.2 | Open | Sep 28, 2026 |
| TENX Tenax Therapeutics Avoid | $1.62 | $1.80 | +11.1% | -7.7 | Closed Sep 1, 2026 | Aug 11, 2026 |
| BEAM Beam Therapeutics Spec buy | $25.18 | $20.65 | -18% | -9.1 | Open | Sep 9, 2026 |
| CBIO Crescent Biopharma Buy | $15.11 | $13.04 | -13.7% | -9.3 | Open | Jul 16, 2026 |
| GUTS Fractyl Health Avoid | $0.90 | $0.96 | +6.7% | -10.2 | Open | Nov 13, 2026 |
| PCSA Processa Pharmaceuticals Spec buy | $2.04 | $1.73 | -15.2% | -11.1 | Open | Jul 30, 2026 |
| CRVO CervoMed Avoid | $1.43 | $1.50 | +4.9% | -12.3 | Open | Nov 9, 2026 |
| CMPS COMPASS Pathways Buy | $7.85 | $7.98 | +1.7% | -12.8 | Open | Feb 23, 2026 |
| GRCE Grace Therapeutics Spec buy | $2.12 | $1.72 | -18.9% | -12.9 | Open | Aug 6, 2026 |
| LEGN Legend Biotech Spec buy | $20.65 | $16.11 | -22% | -13.1 | Open | Aug 12, 2026 |
| MIST Milestone Pharmaceuticals Avoid | $0.36 | $0.41 | +13.2% | -13.6 | Open | Nov 16, 2026 |
| ADMA Adma Biologics Avoid | $9.16 | $10.06 | +9.8% | -13.7 | Closed Aug 6, 2026 | Jul 6, 2026 |
| VIR Vir Biotechnology Buy | $8.99 | $9.25 | +2.9% | -14.3 | Open | Mar 25, 2026 |
| AMLX Amylyx Pharmaceuticals Spec buy | $38.60 | $27.52 | -28.7% | -14.4 | Open | Aug 19, 2026 |
| LGVN Longeveron Spec buy | $8.88 | $8.38 | -5.6% | -14.4 | Closed May 11, 2026 | Mar 16, 2026 |
| SABS SAB Biotherapeutics Spec buy | $3.67 | $2.95 | -19.5% | -15.1 | Open | Jul 16, 2026 |
| ARVN Arvinas Spec buy | $8.40 | $7.42 | -11.7% | -15.6 | Closed Nov 4, 2026 | Aug 5, 2026 |
| BCTX BriaCell Therapeutics Spec buy | $4.47 | $3.76 | -15.9% | -15.6 | Closed Feb 23, 2026 | Feb 2, 2026 |
| ADCT ADC Therapeutics Spec buy | $1.64 | $1.35 | -17.7% | -15.6 | Open | Nov 5, 2026 |
| VRDN Viridian Therapeutics Buy | $29.17 | $30.06 | +3.1% | -17.3 | Open | Feb 5, 2026 |
| HELP Helus Pharma Spec buy | $6.73 | $5.52 | -18% | -18.1 | Closed Mar 9, 2026 | Feb 23, 2026 |
| SLDB Solid Biosciences Spec buy | $8.39 | $6.23 | -25.7% | -18.1 | Open | Aug 7, 2026 |
| NGNE Neurogene Spec buy | $31.45 | $23.10 | -26.6% | -18.4 | Open | Jun 30, 2026 |
| ALLO Allogene Therapeutics Spec buy | $2.25 | $2.07 | -8% | -18.5 | Closed Jun 23, 2026 | Apr 27, 2026 |
| NVCT Nuvectis Pharma Spec buy | $24.48 | $19.20 | -21.6% | -18.6 | Open | Jun 24, 2026 |
| TNGX Tango Therapeutics Buy▵ | $24.87 | $22.11 | -11.1% | -18.8 | Open | May 14, 2026 |
| DYN Dyne Therapeutics Buy | $16.58 | $16.02 | -3.4% | -19.3 | Open | Jan 20, 2026 |
| RNAC Cartesian Therapeutics Buy | $6.93 | $6.12 | -11.7% | -19.7 | Open | May 27, 2026 |
| NRIX Nurix Therapeutics Buy | $15.91 | $14.24 | -10.5% | -20.5 | Open | Apr 13, 2026 |
| BMEA Biomea Fusion Spec buy | $1.53 | $1.49 | -2.6% | -21.6 | Closed Sep 24, 2026 | Apr 28, 2026 |
| LENZ LENZ Therapeutics Spec buy | $5.04 | $3.50 | -30.6% | -21.7 | Open | Aug 12, 2026 |
| ARTV Artiva Biotherapeutics Spec buy | $10.60 | $7.84 | -26% | -23.7 | Closed May 20, 2026 | May 11, 2026 |
| CLDX Celldex Therapeutics Buy | $33.86 | $28.04 | -17.2% | -24.4 | Open | Apr 16, 2026 |
| ENTA Enanta Pharmaceuticals Buy▵ | $13.86 | $14.51 | +4.7% | -24.5 | Closed Jul 6, 2026 | Feb 17, 2026 |
| ERAS Erasca Spec buy | $11.56 | $9.11 | -21.2% | -24.6 | Closed Apr 29, 2026 | Feb 11, 2026 |
| CYDY CytoDyn Avoid | $0.22 | $0.25 | +13.6% | -24.7 | Open | Sep 1, 2026 |
| AKTS Aktis Oncology Buy▵ | $19.73 | $16.31 | -17.3% | -25 | Open | May 12, 2026 |
| CRVS Corvus Pharmaceuticals Buy | $11.50 | $10.17 | -11.6% | -26.1 | Open | May 19, 2026 |
| FBIO Fortress Biotech Spec buy | $2.30 | $2.03 | -11.7% | -26.3 | Closed Oct 2, 2026 | May 14, 2026 |
| CRDL Cardiol Therapeutics Spec buy | $1.02 | $1.01 | -1% | -26.7 | Closed Nov 4, 2026 | Mar 2, 2026 |
| MAIA MAIA Biotechnology Spec buy | $1.31 | $1.25 | -4.6% | -26.9 | Open | Mar 30, 2026 |
| JBIO Jade Biosciences Spec buy | $17.75 | $15.40 | -13.2% | -27 | Open | Jun 2, 2026 |
| ENTA Enanta Pharmaceuticals Spec buy | $13.50 | $8.69 | -35.6% | -27.5 | Closed Nov 17, 2026 | Aug 12, 2026 |
| OMER Omeros Buy | $15.71 | $13.92 | -11.4% | -27.6 | Open | Dec 26, 2025 |
| INBX Inhibrx Biosciences Spec buy | $122.26 | $74.18 | -39.3% | -27.7 | Open | Sep 3, 2026 |
| VERA Vera Therapeutics Buy | $31.27 | $26.20 | -16.2% | -28.1 | Open | Jun 3, 2026 |
| NRXP NRX Pharmaceuticals Spec buy | $3.03 | $2.45 | -19.1% | -28.3 | Open | Apr 27, 2026 |
| DTIL Precision Biosciences Spec buy | $10.60 | $7.05 | -33.5% | -28.9 | Open | Nov 6, 2026 |
| GLSI Greenwich LifeSciences Spec buy | $22.25 | $18.70 | -16% | -29 | Closed Nov 17, 2026 | Jun 5, 2026 |
| RARE Ultragenyx Pharmaceutical Buy▵ | $26.86 | $16.70 | -37.8% | -29 | Open | Aug 12, 2026 |
| KURA Kura Oncology Buy | $9.22 | $7.49 | -18.8% | -29.9 | Open | May 15, 2026 |
| COGT Cogent Biosciences Buy | $37.00 | $27.85 | -24.7% | -30.2 | Open | Apr 20, 2026 |
| CBIO Crescent Biopharma Buy | $18.52 | $15.67 | -15.4% | -31.3 | Closed Jul 15, 2026 | May 11, 2026 |
| OCS Oculis Holding Spec buy | $11.99 | $7.51 | -37.4% | -33 | Open | Aug 4, 2026 |
| PRQR ProQR Therapeutics Spec buy | $1.94 | $1.15 | -40.7% | -33.4 | Open | Sep 10, 2026 |
| VRCA Verrica Pharmaceuticals Spec buy | $5.69 | $3.14 | -44.8% | -34.3 | Open | Aug 28, 2026 |
| ARVN Arvinas Spec buy | $10.78 | $8.14 | -24.5% | -34.6 | Closed Jun 23, 2026 | May 4, 2026 |
| SRPT Sarepta Therapeutics Spec buy | $17.79 | $14.77 | -17% | -35.2 | Open | Feb 13, 2026 |
| QNRX Quoin Pharmaceuticals Spec buy | $6.22 | $3.36 | -46% | -35.4 | Open | Aug 31, 2026 |
| ELTX Elicio Therapeutics Avoid | $2.76 | $3.85 | +39.5% | -35.6 | Closed Jun 18, 2026 | Jun 16, 2026 |
| CGEM Cullinan Therapeutics Buy▵ | $12.57 | $9.28 | -26.2% | -36.6 | Open | Jan 22, 2026 |
| NTLA Intellia Therapeutics Spec buy▵ | $13.20 | $9.78 | -25.9% | -36.7 | Open | Apr 28, 2026 |
| JANX Janux Therapeutics Buy | $14.11 | $10.71 | -24.1% | -36.8 | Open | Apr 29, 2026 |
| ACRS Aclaris Therapeutics Buy | $4.47 | $3.38 | -24.4% | -37.1 | Closed Nov 17, 2026 | Apr 29, 2026 |
| ANAB AnaptysBio Spec buy | $65.58 | $45.61 | -30.5% | -38.1 | Open | May 12, 2026 |
| CCCC C4 Therapeutics Buy▵ | $3.68 | $2.53 | -31.3% | -38.2 | Open | May 13, 2026 |
| ADAG Adagene Spec buy | $1.84 | $1.48 | -19.6% | -39.1 | Open | Jan 2, 2026 |
| AUTL Autolus Therapeutics Spec buy | $1.95 | $1.09 | -44.1% | -39.8 | Open | Aug 4, 2026 |
| IMMX Immix Biopharma Buy | $10.66 | $7.20 | -32.5% | -40.1 | Open | May 12, 2026 |
| XENE Xenon Pharmaceuticals Buy | $57.40 | $38.78 | -32.4% | -41.3 | Open | May 4, 2026 |
| GERN Geron Spec buy | $1.57 | $0.95 | -39.5% | -41.6 | Closed Oct 29, 2026 | Aug 6, 2026 |
| SANA Sana Biotechnology Spec buy | $3.26 | $2.37 | -27.3% | -41.7 | Closed Nov 6, 2026 | Apr 27, 2026 |
| RCUS Arcus Biosciences Buy▵ | $24.69 | $16.39 | -33.6% | -42.5 | Open | Jun 4, 2026 |
| VKTX Viking Therapeutics Buy | $36.41 | $26.88 | -26.2% | -42.5 | Open | Dec 23, 2025 |
| ACRV Acrivon Therapeutics Buy | $1.93 | $1.43 | -25.9% | -43.3 | Open | Jan 8, 2026 |
| SNDX Syndax Pharmaceuticals Buy | $20.56 | $9.20 | -55.3% | -43.9 | Open | Sep 4, 2026 |
| MPLT MapLight Therapeutics Spec buy | $12.92 | $6.57 | -49.1% | -44.1 | Open | Aug 5, 2026 |
| TSHA Taysha Gene Therapies Buy | $6.46 | $4.00 | -38.1% | -47.3 | Open | Apr 27, 2026 |
| GRCE Grace Therapeutics Spec buy▵ | $3.83 | $2.16 | -43.6% | -47.7 | Closed Apr 27, 2026 | Jan 26, 2026 |
| IPSC Century Therapeutics Spec buy | $2.21 | $1.37 | -38% | -48.6 | Open | Jun 9, 2026 |
| ZNTL Zentalis Pharmaceuticals Buy▵ | $3.83 | $1.49 | -61% | -48.7 | Open | Aug 21, 2026 |
| RCKT Rocket Pharmaceuticals Spec buy | $3.59 | $2.11 | -41.2% | -49 | Open | May 11, 2026 |
| SMMT Summit Therapeutics Buy | $15.94 | $10.67 | -33.1% | -49.5 | Open | Feb 20, 2026 |
| CNTB Connect Biopharma Spec buy | $2.54 | $1.24 | -51.2% | -49.5 | Closed Sep 16, 2026 | Aug 13, 2026 |
| CHRS Coherus Oncology Spec buy | $1.26 | $0.64 | -49.3% | -49.7 | Closed Nov 10, 2026 | Aug 6, 2026 |
| NBP NovaBridge Biosciences Spec buy | $1.95 | $0.82 | -57.8% | -49.7 | Open | Jun 30, 2026 |
| DBVT DBV Technologies Buy | $20.27 | $14.70 | -27.5% | -50 | Closed Jul 17, 2026 | Dec 22, 2025 |
| KPRX Kiora Pharmaceuticals Spec buy | $2.32 | $1.56 | -32.8% | -50 | Closed Oct 30, 2026 | Apr 27, 2026 |
| AGMB Agomab Therapeutics Spec buy | $12.68 | $5.92 | -53.3% | -50.4 | Open | Jun 24, 2026 |
| AKBA Akebia Therapeutics Spec buy | $1.16 | $0.70 | -40% | -51.2 | Closed Oct 15, 2026 | May 8, 2026 |
| CYDY CytoDyn Spec buy | $0.32 | $0.22 | -31.2% | -54.1 | Closed Sep 1, 2026 | Apr 27, 2026 |
| ALLO Allogene Therapeutics Spec buy | $1.79 | $0.74 | -58.7% | -54.2 | Open | Jul 16, 2026 |
| CLNN Clene Buy▵ | $5.18 | $3.22 | -37.8% | -55.1 | Open | Jan 12, 2026 |
| GLUE Monte Rosa Therapeutics Buy | $17.50 | $9.07 | -48.2% | -55.2 | Open | Apr 14, 2026 |
| CGTX Cognition Therapeutics Spec buy | $1.08 | $0.69 | -36.4% | -56.1 | Closed Nov 6, 2026 | Mar 9, 2026 |
| KYTX Kyverna Therapeutics Buy▵ | $8.99 | $4.70 | -47.7% | -56.9 | Open | Apr 27, 2026 |
| KTTA Pasithea Therapeutics Buy | $0.77 | $0.43 | -43.6% | -57.4 | Open | May 18, 2026 |
| LRMR Larimar Therapeutics Buy | $5.23 | $2.99 | -42.8% | -57.6 | Open | Mar 2, 2026 |
| OCGN Ocugen Spec buy | $1.65 | $1.00 | -39.4% | -58 | Closed Sep 24, 2026 | Jan 22, 2026 |
| NGEN NervGen Pharma Spec buy | $3.85 | $1.96 | -49.1% | -58.3 | Open | Apr 27, 2026 |
| IMTX Immatics Buy | $10.45 | $6.29 | -39.8% | -59.4 | Open | Jan 2, 2026 |
| MDNAF Medicenna Therapeutics Spec buy | $0.32 | $0.16 | -50.3%* | -59.4 | Closed Nov 18, 2026 | May 26, 2026 |
| INAB IN8bio Spec buy | $1.56 | $0.98 | -37.2% | -60.4 | Closed Aug 7, 2026 | Jun 2, 2026 |
| ARTV Artiva Biotherapeutics Spec buy | $7.27 | $4.28 | -41.2% | -61.1 | Closed Oct 28, 2026 | Jun 9, 2026 |
| BBOT BridgeBio Oncology Therapeutics Spec buy | $6.75 | $1.94 | -71.3% | -62.4 | Open | Sep 9, 2026 |
| IMRX Immuneering Spec buy▵ | $6.66 | $3.46 | -48% | -65.8 | Open | Dec 29, 2025 |
| VTVT vTv Therapeutics Spec buy | $36.41 | $17.29 | -52.5% | -68.5 | Open | Feb 4, 2026 |
| GANX Gain Therapeutics Buy▵ | $3.19 | $1.71 | -46.4% | -69 | Closed Oct 2, 2026 | Dec 22, 2025 |
| GPCR Structure Therapeutics Buy | $43.56 | $18.17 | -58.3% | -69.1 | Open | Apr 28, 2026 |
| ATHE Alterity Therapeutics Buy | $4.73 | $1.87 | -60.5% | -71.9 | Open | May 1, 2026 |
| ADCT ADC Therapeutics Avoid | $1.01 | $1.73 | +71.3% | -73.6 | Closed Oct 9, 2026 | Aug 14, 2026 |
| CTMX CytomX Therapeutics Spec buy | $4.46 | $1.94 | -56.5% | -75.9 | Open | Mar 23, 2026 |
| CRBU Caribou Biosciences Spec buy | $1.94 | $0.62 | -68.2% | -79.7 | Closed Oct 7, 2026 | May 8, 2026 |
| CABA Cabaletta Bio Buy▵ | $3.31 | $1.02 | -69.2% | -80.3 | Open | May 15, 2026 |
| BIOA BioAge Labs Buy | $15.34 | $5.10 | -66.8% | -80.5 | Open | May 18, 2026 |
| CATX Perspective Therapeutics Buy▵ | $2.73 | $1.21 | -55.7% | -80.9 | Closed Oct 26, 2026 | Jan 5, 2026 |
| PMN ProMIS Neurosciences Spec buy | $14.06 | $3.00 | -78.7% | -81.5 | Closed Nov 2, 2026 | Jul 29, 2026 |
| LXEO Lexeo Therapeutics Spec buy | $8.12 | $2.85 | -64.8% | -82.1 | Open | Jan 12, 2026 |
| STRO Sutro Biopharma Buy▵ | $33.59 | $8.92 | -73.4% | -82.6 | Open | Apr 27, 2026 |
| TARA Protara Therapeutics Spec buy | $7.43 | $2.32 | -68.8% | -83.2 | Open | Feb 23, 2026 |
| ALT Altimmune Buy▵ | $4.09 | $1.53 | -62.6% | -83.5 | Open | Jan 5, 2026 |
| ERAS Erasca Avoid | $9.11 | $19.50 | +114.1% | -93.5 | Closed Jul 14, 2026 | Apr 29, 2026 |
| WVE Wave Life Sciences Buy▵ | $13.44 | $2.84 | -78.9% | -96.5 | Open | Mar 3, 2026 |
| CUE Cue Biopharma Spec buy | $26.91 | $2.83 | -89.5% | -101.4 | Open | Jun 3, 2026 |
| MIST Milestone Pharmaceuticals Buy | $2.20 | $0.36 | -83.4% | -103.5 | Closed Nov 16, 2026 | Dec 16, 2025 |
| EYPT EyePoint Buy | $13.34 | $0.41 | -96.9% | -114.4 | Closed Oct 20, 2026 | May 1, 2026 |
| GUTS Fractyl Health Spec buy | $25.08 | $0.90 | -96.4% | -115.5 | Closed Nov 13, 2026 | Jan 7, 2026 |
| ABOS Acumen Pharmaceuticals Spec buy▵ | $2.71 | $0.24 | -91.1% | -116.2 | Closed Nov 2, 2026 | Mar 23, 2026 |
| QURE uniQure Avoid | $17.99 | $46.29 | +157.3% | -146.6 | Closed Jun 18, 2026 | Mar 9, 2026 |
| REPL Replimune Group Avoid | $1.70 | $9.00 | +429.4% | -428.3 | Closed Jun 1, 2026 | Apr 13, 2026 |
No calls match these filters.
On BD's watch list
- PRME Prime Medicine Watch
Prime has the best clinical evidence in gene editing but no issued patents, a going-concern note, $168M of non-cancellable rent, and prices in vivo liver prime editing working on one dosed patient and a mouse — wait for a human pharmacodynamic datapoint or a materially lower price.
- RNTX Rein Therapeutics Watch
Interim was blinded and uninformative on efficacy, but faster-than-expected enrollment pulls the real binary into 2027; drug is near cash value but reverse split and post-topline raise both look likely, so it stays on the watch list rather than a buy.
-
The Lilly supply deal puts the CDK4/6 combination on the calendar and cash came in ahead of estimate, but no patient neutrophil data exist and the Incyte option decision remains pending, so the watch stance is unchanged.
-
Longer follow-up shows rinzimetostat's landmark rPFS fell from 84% to 59%, matching but not beating mevrometostat, upgrade criteria not met, and value now depends almost entirely on Pfizer's February readout.
- IDYA IDEAYA Biosciences Watch
FDA alignment on a NEC registrational path widens the IDE849 market but rests on 7 confirmed responders from 19 Chinese patients; Western efficacy data still not public and spending commitments are growing ahead of the data.
- GNLX Genelux Watch
With share count up 26% YTD, accrued trial bills doubled, working capital cushion thin, and OnPrime topline due within weeks, waiting for the data and the financing that follows is more defensible than guessing ahead of the print.
- ANRO Alto Neuroscience Watch
Pramipexole's antidepressant effect is well-validated but at ~$1.1B EV the stock already prices a likely PACE-1 win, ALTO-207's own data are thin (32 patients, single-blind, secondary endpoint), and the moat around two generic drugs rests on method claims expiring ~2038-2039 with no NCE exclusivity.
- MBX MBX Biosciences Watch
At ~$2.4B EV the stock already prices a Phase 3 win; canvuparatide has not been shown to beat Yorvipath on anything but injection frequency, there is no issued U.S. patent, and the obesity leg has no interpretable data yet.
- NKTR Nektar Therapeutics Watch
Runway into Q3 2028 reaffirmed and burn partly explained by prepayments, but ZENITH AD-2 redesign as a TCS-combination trial removes naïve monotherapy replication; a small starter position remains reasonable ahead of Q1 2027 durability data.
-
CMC appears on track for a year-end IND, but first progressions to muscle-invasive disease, a drifting BCG-unresponsive 12-month CR, a pivoting IR cohort, and contradictory funding language keep the Watch stance intact with no reason to hurry.
- MGTX MeiraGTx Watch
The predicted equity raise arrived via a new $100M ATM, Hologen's $95M remains unpaid, and none of the three stated upgrade triggers (Hologen payment, AQUAx2 readout, sub-$9 print) has fired, so the watch stance is maintained.
-
HUNT1 acquisition adds cheap optionality but runway slipped a quarter to Q2 2028 and Lineage now has a second program whose trial timeline it doesn't control; the Roche OpRegen controlled-trial trigger remains the only event that re-rates the stock.
- KOD Kodiak Sciences Hold
First ATM draw of $68.9M at ~$100/share improves the treasury with minimal dilution, but ALTO's primary endpoint was lowered to non-inferiority and the AI-guided dosing label risk is new; hold house money into PEAK as the cleanest remaining IL-6 test.
-
Q3 cash burn of ~$56.7M passed the $60M test and ATM issuance paused, keeping both 4FRONT readouts funded from cash, but expense run-rate remains ~$68M with 4SIGHT costs only beginning; patient capital might consider a small position at ~$12 sized to a non-inferiority coin flip.
-
LEGACY's Q4 start is now formally contingent on financing, cash has fallen to $69.7M with $20.7M in committed manufacturing obligations, and a $150M raise at current prices implies ~53% dilution — the raise remains the event to engage around, not ahead of.
- EIKN Eikon Therapeutics Watch
Melanoma interim slipped to 1H 2027 and reframed as a futility test, but extended runway now reaches past the readout, reducing forced-raise risk; trigger reset but still unfired.
- ALMS Alumis Watch
Envu is an approvable, royalty-free, top-tier oral psoriasis drug at a reasonable EV, but the going-concern qualification, near-certain dilutive raise of 30-40%, fourth-to-market BID positioning, and failed lupus trial make it not cheap enough to own the financing.
- AVBP ArriVent BioPharma Watch
At ~$306M EV the stock is roughly fairly priced for two binary assets with no dated readout on the lead; FURVENT missed on a comparator anomaly rather than drug failure, but ALPACCA faces the same measurement risk against stronger comparators and ARR-217's confirmed response rate needs validation in a larger, more mature cohort.
- UPB Upstream Bio Watch
Verekitug has two positive Phase 2s at near-zero enterprise value, but the Phase 3 appears mis-specified for a broad label, uses an untested dose, faces longer-acting competitors already in Phase 3, and requires a certain large dilutive financing before any data.
-
The resubmission remains on track but the CNPV will expire unused, eliminating the vaping program's only accelerant; the two core unresolved questions (Sopharma arbitration, NCE exclusivity) remain open.
- PALI Palisade Bio Watch
First patient dosed and balance sheet intact, but the dose bridge remains unproven, a new single-source WuXi API supply risk emerged ahead of the December BIOSECURE list deadline, and the lower EV improves entry math without improving the drug's odds.
- INKT MiNK Therapeutics Watch
The ARDS readout has slipped a second time to 2H2027, cash is down to $7.5M with a raise now explicitly on the table, and the endpoint has shifted from survival to ECMO prevention; the science hasn't worsened but the structure has, keeping the stock on watch with no new buying until a U.S. patient is dosed, FDA aligns on the adaptive design, and a raise clears.
-
FDA feedback was better than feared with a workable 300-patient brain-metastasis Phase 3 and accelerated-approval path, but the trial remains unfunded with no partner announced and the company has disclosed it needs substantial additional capital.
- TGTX Tg Therapeutics Watch
Q3 earnings quality improved with 33% operating margin and guidance raised to ~$1B, but U.S. sales flattened sequentially, a new tariff emerged, and the valuation has stretched to ~10x sales ahead of the SubQ readout.
- SEPN Septerna Watch
Q1 2027 readout remains on schedule but the stock is now ~11% above the probability-weighted fair value and near its 52-week high, with insiders and smart money selling into strength, making the watch stance unchanged.
-
Transform-HTN confirms durable blood-pressure effect and manageable potassium at 48 weeks, but hyponatremia remains undisclosed, the withdrawal sub-study is unreported, and the core commercial problem — second to market against AstraZeneca with a generic payer wall — is unchanged.
- MAZE Maze Therapeutics Watch
HORIZON enrollment to 50+ patients improves the quality of the coming binary readout but provides no new efficacy data; at ~$35 and ~$1.7B EV the stock has moved above the probability-weighted value with no new evidence, so the WATCH stance is maintained pending the non-FSGS cohort clearing ≥30% uACR with uPCR disclosed.
- CGEN Compugen Watch
MAIA-ovarian fully enrolled with Q1 2027 readout locked, cash floor intact at ~$85M EV, but 'totality of the data' wording raises goalpost concerns and the core tension from June remains unchanged.
- CAMP Camp4 Therapeutics Watch
CAMP4 has a genuinely novel upregulation platform in an unmet disease but zero human data, no issued patents, no US sites, no PD biomarker, and the nearest class precedent just failed Phase 3; at $4.06 the stock prices roughly fair odds on a 2028 coin flip.
- BCAX Bicara Therapeutics Watch
FORTIFI-HN01 cleared enrollment gate on schedule and valuation has compressed to ~$240M enterprise value, but burn strains runway, WuXi Biologics BIOSECURE exposure was underweighted, and efficacy remains single-arm until mid-2027.
- ANTX AN2 Therapeutics Watch
IND cleared on schedule and cash covers all 2027 readouts, but no PV patient has been dosed and the scientific case is unchanged; maintain Watch until PV Part 1 data demonstrate hematocrit control without a platelet problem.
- ANNX Annexon Watch
ANX1502 sidelined to formulation lab and GBS BLA still needs FDA alignment, but ARCHER II trial execution remains clean and balance sheet is adequate into 2028.
-
RAP-219 has a validated mechanism and ample cash but the epilepsy case rests on an uncontrolled 30-patient study, the only randomized result is a marginal p=0.045 with twice the dropouts on drug, and the next efficacy readout is ~two years away.
-
VY1706 dosing slipped from Q4 2026 to 'next few months,' a September layoff appeared only in the 10-Q, ATM selling at lower prices, and stock trades ~$25M below cash; proxy waiting game still better played after the data.
-
APEX dated to end of January 2027 with ~$153M EV over cash creating asymmetric setup on paper, and AZD5462 LUMINARA mildly supportive of RXFP1 mechanism, but bear case (relaxin history, CADENCE 6MWD flatline, WuXi sole-sourcing) unchanged; small position may warrant sizing for binary-event tolerant readers but watch-list stance maintained for everyone else.
- SCYX Scynexis Watch
The stock is back at roughly half of net cash with both Phase 1 gates cleared and real kidney expertise on staff, but an ~$8M quarterly burn strains the 2029 runway, a financing toolkit (shelf + ATM) signals likely dilution before the Q4 2027 binary, and the mechanism remains unproven in a human kidney.
- LBRX LB Pharmaceuticals Watch
Q3 cash of $403.8M and NOVA-2 on track pass two of three thesis checks, but a newly disclosed $200M ATM introduces a soft ceiling on pre-data rallies without yet tripping the PASS trigger; the SPECULATIVE BUY entry level remains ~$32.
- KROS Keros Therapeutics Watch
Keros passed capital-allocation tests (buyback executed, ATM unused) but the preclinical burn mix is unchanged and no upgrade trigger (positive RENEW or meaningful capital-return commitment) has fired.
- INMB Inmune Bio Watch
Q3 shows $16.3M cash with runway only to Q3 2027, the Australian rebate bridge is gone, the BLA date has slipped again, and the confirmatory trial has dropped off the milestone calendar, but the February MHRA filing date held and the voucher thesis remains intact, keeping the watch stance with a negative tilt.
-
STRATUS-HCM delivers the placebo-controlled design with separate cohorts and objective peak VO2 primary endpoint the author asked for, but trough gradient question remains open, nHCM has no Phase 2 VO2 data, and at ~$2.62B EV the price trigger of $25–27 has not been met.
-
Record Q3 thalassemia revenue of $48.7M and 75% six-month persistence strengthen the launch floor, but the SCD leg is unchanged — a REMS still looks likely, HIBISCUS reports before the February 1 label, and the voxelotor precedent remains; waiting for ASH and February 1 is still the sensible course.
- ACET Adicet Bio Watch
A going-concern warning, ADI-212 enrollment slip, and stock at ~$2.92 (deeply below $100.9M cash) make any equity raise severely dilutive; the science is unchanged but the financing gap is now the dominant risk, and the patient approach is to wait for the company to price its deal before stepping in.
- XFOR X4 Pharmaceuticals Watch
K2 covenant terms failed the 'benign' gate, locking up ~$60M from October 2027 and making a pre-topline equity raise likely, while valuation has drifted higher without any improvement in the probability of success; enrollment close remains the key remaining gate.
- RLAY Relay Therapeutics Watch
No new clinical data and a ~$4.0B market cap still pricing in a Phase 3 win on open-label numbers; the key vascular anomaly catalyst is now dated for Dec 14, warranting continued watch until confirmed, durable responses at expansion doses are shown.
- OKUR OnKure Therapeutics Watch
Q3 10-Q confirms no ATM sales and cash on plan, but PIKture-01 data remain absent and manufacturing is single-sourced in China, so the watch stance is maintained pending year-end data.
- NAMS NewAmsterdam Pharma Watch
Q3 cash held at $643.1M with ATM undrawn, but the UK launch slipped to 2027, a new MFN pricing risk disclosure suggests European prices could cap U.S. upside, and the PREVAIL DSMB recommendation remains the sole binary with no U.S. NDA date in sight.
-
Tranche 4 lapsed and IZAR-2 slipped to Q1 2027, worsening the clock, but valuation improved materially; the real de-risking event (HS label efficacy table content) has moved to 2027.
- HRMY Harmony Biosciences Watch
BP-205 MAD data passed safety checks but showed no efficacy signal, the Delaware ruling is now pushed to February 2027, growth slowed to 12%, and royalties are taking a larger share of revenue — the binary remains unresolved.
-
Well-engineered LPA1 antagonist with validated class and funded Phase 2, but PIPE-791 has never been tested in IPF patients, its differentiation claim met a bad data point in Bristol's 120 mg arm, the FDA's blood-pressure concern has kept PROPEL-IPF out of the US, and all patents are pending.
-
Q3 headline beat was driven by a one-time CareMed stocking order masking flat underlying ORLADEYO revenue, adult capsule volume is already slipping, and neither de-risking trigger for an upgrade has fired.
- ACIU AC Immune Watch
Runway extended to Q1 2028 on lean burn, but the hsCRP readout slipped to H1 2027 and VacSYn's missing biomarker numbers remain unreported, leaving 2026 with no quantified efficacy-adjacent result on any owned asset.
-
The plenary added lower-GI and large-polyp data and a strategically credentialed new chair, but the FDA registrational-path endpoint — the single fact that determines REC-4881's value and filing timeline versus the April 2029 patent expiry — has slipped to 'later this year', leaving the watch stance unchanged.
- STOK Stoke Therapeutics Watch
Zero EMPEROR discontinuations and minimal ATM use are positive, but accelerating burn reduces cash at the Q3 2027 readout and makes a pre-data raise more likely, so patience until 1H 2027 checkpoints remains warranted.
- INSM Insmed Watch
Q3 beat validates the launch curve and collapses the financing bear case, but net-versus-gross patient adds remain undisclosed and TPIP data has drifted later, so the upgrade trigger has not yet fired.
-
The Duravelo-2 randomized data readout has slipped a year to 2H 2027, removing the near-term re-rating catalyst; burn is improving but no capital-allocation event has occurred, so the watch stance is maintained with no new reason to step in.
-
Relcobatinib has a winnable Phase 3 but ENABLE-2 is designed to beat generic 2G TKIs rather than asciminib or MK-4208, and at $41.93 the stock already prices a successful 2L+ franchise plus much of a first-line future that has no trial yet.
-
Telix's profitable gallium imaging franchise lacks durable patent protection and is funding an unproven therapeutics strategy via dilutive M&A; wait for the ITM vote, pricing data against new competition, and BiPASS readout before owning it.
-
ADPKD program gains a more credible regulatory endpoint (htTKV) and a seasoned CMO, but its readout slipped to 1H 2029 past the funded runway, and the lead Alport asset's efficacy case is still n=3 on an unvalidated surrogate.
- ABVX Abivax Watch
Strong Phase 3 efficacy but all six malignancies on the 50 mg dose and a label decision a year away make the current ~$6.2B EV insufficient discount to buy.
- ANIX Anixa Biosciences Watch
Cohort 5 produced only one stable-disease result (not an objective response) and no DLTs, modestly de-risking safety but leaving efficacy and pharmacodynamics unproven; Watch List maintained pending RECIST-confirmed responses with denominators.
- QTTB Q32 Bio Watch
EADV delivered the JAK-naive/experienced split (mechanistically coherent) but the ITT mean remains withheld and responder-counting questions go unanswered, leaving the author short of speculative-buy conviction despite the enterprise value collapsing to ~$12M.
- TYRA Tyra Biosciences Watch
RA Capital's $200M add and Paradigm's new 5.8% stake confirm specialist money read the 57% CR as a dosing problem not a drug failure, strengthening the ownership leg of the thesis, but efficacy at 70 mg remains the only thing that can convert the rating.
- KZIA Kazia Therapeutics Watch
Pharmacodynamics are genuinely interesting but every efficacy number comes from six unblinded patients on an active backbone with one ineligible patient providing the only complete response; a control arm is needed before taking a position.
- ENTX Entera Bio Watch
Despite a de-risked mechanism and strong balance sheet post-financing, the 21-patient efficacy signal, untested Phase 3 dose, primary endpoint outside FDA's qualified 24-month context of use, and 85% post-financing markup into a 26-month catalyst desert make this the wrong entry at the wrong price.
The full record
| Category | # calls | Beat XBI | Avg return | Avg vs XBI |
|---|---|---|---|---|
| Open buy calls | 122 | 26% | -9.9% | -15 |
| Core | 64 | 27% | -4.8% | -13.4 |
| Speculative | 58 | 26% | -15.6% | -16.8 |
| Open avoid calls | 51 | 75% | — | +24.8 |
| Closed buy calls | 44 | 14% | -20.5% | -33.7 |
| Closed avoids | 22 | 59% | — | -15.8 |
2 published calls are held back from this session's figures, so the counts above are short by 2: MDNAF — its entry session has not traded yet; SLS — its entry session has not traded yet. Nothing has been removed from the record — each returns as soon as it can be priced honestly.
Hypothetical editorial track record, not a managed portfolio — past performance does not guarantee future results. Not investment advice.